Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Shionogi Of Japan, GSK Of U.K. Report Good Results From HIV/AIDS Drug

This article was originally published in PharmAsia News

Executive Summary

Japan's Shionogi reports strong encouragement from Phase II trials for its drug to treat HIV/AIDS. Shionogi is testing the drug as part of a joint development deal with GlaxoSmithKline of the United Kingdom. Their study indicated the S/GSL1349572 drug lowered the virus to levels that could not be detected in 70 percent of the participants. After 10 days, none of the South Africa patients displayed drug resistance, the study said. The drug relies on blocking the integrase enzyme. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts